A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma

Table 1

Patient characteristics.

Age	Gender	NY-ESO-1 immuno-histochemistry	HLA-A2	HLA-DP4	ECOG performance status	Time to progression; (months)	Overall survival; (months)
43	F	3+	+	+	1	1.9	3.8
26	F	4+	+	+	1	0.9	19.7
56	M	3+	+	+	0	1.9	13.7
32	F	3+	−	+	1	2.1	3.2
57	F	3+	−	−	2	0.5	0.8
23	M	2+	+	+	1	1.8	13.7